Saturday 17 October 2026
Export EXEL’s income statement to Excel — free account
Exelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024. In the quarter to June 2026, revenue grew 10.6%, EPS grew 25.0% and free cash flow grew 557.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
62.11
0.72
−1.15%
Follow EXEL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
16.49 | 13.70 | 15.17 | 16.79 |
+8 more quarters Free account |
P/S ratio |
5.60 | 4.66 | 5.13 | 4.84 | |
P/FCF ratio |
11.78 | 12.24 | 14.10 | 14.89 | |
P/Operating CF |
44.34 | 43.99 | 35.69 | 38.18 | |
P/B ratio |
7.40 | 5.72 | 5.51 | 5.13 | |
Price to Tangible BV |
7.67 | 5.92 | 5.67 | 5.29 | |
EV/Sales |
5.27 | 4.35 | 4.68 | 4.42 | |
EV/EBITDA |
12.83 | 10.70 | 12.06 | 12.19 | |
EV/Operating CF |
10.84 | 11.17 | 12.29 | 12.79 | |
EV/FCF |
11.08 | 11.41 | 12.87 | 13.60 | |
Quick Ratio |
3.21 | 2.98 | 3.32 | 3.47 | |
Current Ratio |
3.46 | 3.26 | 3.56 | 3.75 | |
Net Debt/EBITDA |
(3.29) | (3.01) | (4.37) | (4.05) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.94 | 0.87 | 0.80 | 0.79 | |
Operating CF/Net income |
1.45 | 1.20 | 1.36 | 1.50 | |
Capex/Depreciation |
(1.33) | (0.29) | (1.03) | (0.91) | |
Research and Development Expense of Revenue |
33.72% | 32.73% | 35.62% | 33.32% | |
Selling, General and Administrative Expense of Revenue |
23.48% | 22.86% | 20.55% | 20.69% | |
Intangible Assets out of Total Assets |
0.03 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
5.18% | 4.76% | 3.36% | 5.17% | |
Graham Net Nets |
0.04 | 0.05 | 0.06 | 0.07 | |
Graham Number |
23.36 | 22.97 | 22.75 | 21.11 | |
Earnings Yield |
6.07% | 7.30% | 6.59% | 5.96% | |
Free Cash Flow Yield |
8.49% | 8.17% | 7.09% | 6.71% | |
Revenue per Share |
2.51 | 2.36 | 2.20 | 2.23 | |
Operating CF per Share |
1.23 | 0.97 | 1.23 | 1.08 | |
Capex per Share |
(0.04) | (0.01) | (0.03) | (0.03) | |
Free Cash Flow per Share |
1.19 | 0.97 | 1.20 | 1.06 | |
Cash per Share |
3.35 | 3.01 | 3.90 | 3.68 | |
Shareholders Equity per Share |
7.35 | 7.49 | 7.96 | 8.05 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.35 | 7.49 | 7.96 | 8.05 | |
Free Cash Flow |
298.43 | 249.81 | 326.36 | 283.59 | |
Working Capital |
888.90 | 837.66 | 1,037.65 | 1,028.48 | |
Capital Expenditures |
(9.32) | (2.03) | (7.16) | (6.73) | |
Net Current Asset Value |
600.35 | 550.79 | 760.19 | 739.41 | |
EV/EBIT |
13.21 | 11.02 | 12.46 | 12.65 | |
Capex to Sales |
0.01 | 0.00 | 0.01 | 0.01 | |
Price to Operating Income |
14.05 | 11.83 | 13.65 | 13.85 | |
| Other line items | |||||
Average Receivables |
307.28 | 305.29 | 276.18 | 289.72 | |
Average Payables |
32.44 | 33.50 | 33.91 | 42.33 | |
Average Inventory |
26.11 | 25.73 | 22.04 | 24.21 | |
Average Assets |
2,586.16 | 2,715.42 | 2,896.06 | 2,891.91 | |
Average Common Equity |
1,938.65 | 2,033.39 | 2,202.76 | 2,218.06 |
Columns are period end dates